WallStreetZenWallStreetZen

NASDAQ: DYAI
Dyadic International Inc Stock

$1.63+0.05 (+3.16%)
Updated Mar 27, 2024
DYAI Price
$1.63
Fair Value Price
N/A
Market Cap
$46.96M
52 Week Low
$1.19
52 Week High
$2.40
P/E
-7.09x
P/B
6.14x
P/S
18.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.96M
Earnings
-$6.87M
Gross Margin
21.2%
Operating Margin
-232.41%
Profit Margin
-232.4%
Debt to Equity
0.21
Operating Cash Flow
-$7M
Beta
0.81
Next Earnings
Mar 28, 2024
Ex-Dividend
N/A
Next Dividend
N/A

DYAI Overview

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DYAI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

DYAI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DYAI is good value based on its book value relative to its share price (6.14x), compared to the US Biotechnology industry average (6.2x)
P/B vs Industry Valuation
DYAI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DYAI due diligence checks available for Premium users.

Be the first to know about important DYAI news, forecast changes, insider trades & much more!

DYAI News

Valuation

DYAI fair value

Fair Value of DYAI stock based on Discounted Cash Flow (DCF)
Price
$1.63
Fair Value
$1.73
Undervalued by
5.87%
DYAI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

DYAI price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-7.09x
Industry
14.3x
Market
44.45x

DYAI price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.14x
Industry
6.2x
DYAI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

DYAI's financial health

Profit margin

Revenue
$397.1k
Net Income
-$1.6M
Profit Margin
-406.6%
DYAI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
DYAI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$9.3M
Liabilities
$1.6M
Debt to equity
0.21
DYAI's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DYAI's short-term assets ($9.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DYAI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.0M
Investing
$3.5M
Financing
$0.0
DYAI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

DYAI vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
DYAI$46.96M+3.16%-7.09x6.14x
EYEN$46.72M-2.38%-1.49x5.19x
BOLT$46.52M+2.52%-0.67x0.41x
CARA$47.50M+19.04%-0.40x0.83x
ESLA$45.76M-0.79%-0.43x5.06x

Dyadic International Stock FAQ

What is Dyadic International's quote symbol?

(NASDAQ: DYAI) Dyadic International trades on the NASDAQ under the ticker symbol DYAI. Dyadic International stock quotes can also be displayed as NASDAQ: DYAI.

If you're new to stock investing, here's how to buy Dyadic International stock.

What is the 52 week high and low for Dyadic International (NASDAQ: DYAI)?

(NASDAQ: DYAI) Dyadic International's 52-week high was $2.40, and its 52-week low was $1.19. It is currently -32.08% from its 52-week high and 36.97% from its 52-week low.

How much is Dyadic International stock worth today?

(NASDAQ: DYAI) Dyadic International currently has 28,811,061 outstanding shares. With Dyadic International stock trading at $1.63 per share, the total value of Dyadic International stock (market capitalization) is $46.96M.

Dyadic International stock was originally listed at a price of $3.55 in Apr 18, 2019. If you had invested in Dyadic International stock at $3.55, your return over the last 4 years would have been -54.08%, for an annualized return of -17.68% (not including any dividends or dividend reinvestments).

How much is Dyadic International's stock price per share?

(NASDAQ: DYAI) Dyadic International stock price per share is $1.63 today (as of Mar 27, 2024).

What is Dyadic International's Market Cap?

(NASDAQ: DYAI) Dyadic International's market cap is $46.96M, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Dyadic International's market cap is calculated by multiplying DYAI's current stock price of $1.63 by DYAI's total outstanding shares of 28,811,061.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.